S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

Medifast Stock Forecast, Price & News

+3.36 (+1.75%)
(As of 01/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
142,788 shs
Average Volume
128,819 shs
Market Capitalization
$2.27 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

Medifast logo

About Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand-a highly competitive and effective lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.


See More Headlines

Industry, Sector and Symbol

Miscellaneous food preparations & kindred products
Personal Products
Year Founded

Sales & Book Value

Annual Sales
$934.84 million
Cash Flow
$9.44 per share
Book Value
$13.36 per share


Net Income
$102.86 million
Pretax Margin




Free Float
Market Cap
$2.27 billion

Company Calendar

Ex-Dividend for 11/8 Dividend
Last Earnings
Dividend Payable
Ex-Dividend for 2/8 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

3.41 out of 5 stars

Consumer Staples Sector

2nd out of 184 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 6 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 3.3Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -

Medifast (NYSE:MED) Frequently Asked Questions

Is Medifast a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast
or view top-rated stocks.

How has Medifast's stock been impacted by COVID-19?

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MED shares have increased by 177.4% and is now trading at $195.39.
View which stocks have been most impacted by COVID-19

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Medifast

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) announced its quarterly earnings results on Thursday, November, 4th. The specialty retailer reported $3.56 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.92 by $0.64. The specialty retailer earned $413.40 million during the quarter, compared to analysts' expectations of $402.80 million. Medifast had a trailing twelve-month return on equity of 87.41% and a net margin of 11.18%. The company's revenue was up 52.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.91 earnings per share.
View Medifast's earnings history

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, December 9th. Shareholders of record on Tuesday, December 21st will be paid a dividend of $1.42 per share on Tuesday, February 8th. This represents a $5.68 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Monday, December 20th.
View Medifast's dividend history

Is Medifast a good dividend stock?

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 2.96%. Medifast has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Medifast is 42.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 35.08% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

What guidance has Medifast issued on next quarter's earnings?

Medifast updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided EPS guidance of $13.270-$13.960 for the period, compared to the Thomson Reuters consensus estimate of $13.930. The company issued revenue guidance of $1.51 billion-$1.53 billion, compared to the consensus revenue estimate of $1.52 billion.

What price target have analysts set for MED?

3 equities research analysts have issued twelve-month target prices for Medifast's shares. Their forecasts range from $265.00 to $400.00. On average, they anticipate Medifast's stock price to reach $338.00 in the next twelve months. This suggests a possible upside of 73.0% from the stock's current price.
View analysts' price targets for Medifast
or view top-rated stocks among Wall Street analysts.

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Daniel R. Chard, Executive Chairman & Chief Executive Officer
  • James P. Maloney, Chief Financial Officer
  • William Baker, Executive Vice President-Information Technology
  • Jason L. Groves, Secretary, Executive VP & General Counsel
  • Nicholas M. Johnson, EVP-Coach Success & Market President

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by many different institutional and retail investors. Top institutional investors include Nordea Investment Management AB (0.47%), Russell Investments Group Ltd. (0.26%), Chickasaw Capital Management LLC (0.25%), Campbell Newman Asset Management Inc. (0.12%), State of Alaska Department of Revenue (0.07%) and Agate Pass Investment Management LLC (0.06%). Company insiders that own Medifast stock include Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast

Which major investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Crossmark Global Holdings Inc., Chickasaw Capital Management LLC, Nordea Investment Management AB, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, and Newbridge Financial Services Group Inc.. Company insiders that have sold Medifast company stock in the last year include Constance J Hallquist, Daniel R Chard, Kevin G Byrnes, and Scott Schlackman.
View insider buying and selling activity for Medifast
or view top insider-selling stocks.

Which major investors are buying Medifast stock?

MED stock was purchased by a variety of institutional investors in the last quarter, including Agate Pass Investment Management LLC, National Bank of Canada FI, Carolina Wealth Advisors LLC, First Hawaiian Bank, Strs Ohio, Campbell Newman Asset Management Inc., and Brookstone Capital Management.
View insider buying and selling activity for Medifast
or or view top insider-buying stocks.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $195.39.

How much money does Medifast make?

Medifast has a market capitalization of $2.27 billion and generates $934.84 million in revenue each year. The specialty retailer earns $102.86 million in net income (profit) each year or $13.34 on an earnings per share basis.

How many employees does Medifast have?

Medifast employs 713 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

Where are Medifast's headquarters?

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at (410) 581-8042, via email at [email protected], or via fax at 410-581-8070.

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.